clinical study

Vivus Adds 12% in Early Trading on Qnexa Study Results

blood pressure, clinical study, diet, drug, fat, health, lipid, medical, medication, obesity, pharma, pill, placebo, qnexa, trade, vivus, vvus, weight loss

Vivus (VVUS) is up by double digits in early trading, after it says long-term data demonstrated patients treated with the investigational drug QNEXA for two years showed reductions in blood pressure and the use of antihypertensive

By FNNO Staff
fnnonline@gmail.com

Latest News from FNNO

Shares of Xylem Have Risen Above Previou...

Xylem (NYSE:XYL) traded at a new 52-week high today of $39.84. Approximately 892,000 s ...

Shares of Exxon Mobil Have Risen Above P...

Exxon Mobil (NYSE:XOM) traded at a new 52-week high today of $103.81. Approximately 11 ...

WR Berkley: The Winning Streak Continues...

WR Berkley (NYSE:WRB) traded today at a new 52-week high of $46.25. So far today appro ...

Westar Energy Looks to Continue to Trade...

Westar Energy (NYSE:WR) traded today at a new 52-week high of $37.40. Approximately 41 ...

WPX Energy Looks to Continue to Trade Ab...

WPX Energy (NYSE:WPX) traded today at a new 52-week high of $23.91. So far today appro ...

Whiting Petroleum: 52-Week High Recently...

Whiting Petroleum (NYSE:WLL) traded at a new 52-week high today of $80.86. This new hi ...

Recent 52-Week High Exceeded in Shares o...

Shares of Westmoreland Coal (AMEX:WLB) traded today at $37.10, breaking its 52-week hig ...

Recent 52-Week High Exceeded in Shares o...

Windstream (NASDAQ:WIN) traded today at a new 52-week high of $10.19. This new high wa ...

Most Popular Video News